Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor Tcells specific for tumor antigen GD2

Cytotherapy

Volumn 17, Issue 4, 2015, Pages 487-495

  Gargett, Tessa ^a   Brown, Michael P ^a,b,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Anti CD3 and anti CD28 stimulation; Chimeric antigen receptor T cells; Effector function; IL 15; IL 2; IL 7; Immune phenotype; Retronectin

Indexed keywords

ANTIGEN GD2; CD28 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; CELL PROTEIN; CHEMOKINE RECEPTOR CCR7; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 7; RETRONECTIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FIBRONECTIN; HYBRID PROTEIN; IL15 PROTEIN, HUMAN; IL2 PROTEIN, HUMAN; IL7 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CELL EXPANSION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; ADOPTIVE TRANSFER; CELL CULTURE TECHNIQUE; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PHENOTYPE; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; FIBRONECTINS; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; INTERLEUKIN-7; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 84924328621     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.12.002     Document Type: Article

References (48)

1. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
2. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557.
3. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
4. Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. JImmunother 2013, 36:133-151.
5. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993, 90:720-724.
6. Gade T.P., Hassen W., Santos E., Gunset G., Saudemont A., Gong M.C., et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 2005, 65:9080-9088.
7. Brentjens R.J., Santos E., Nikhamin Y., Yeh R., Matsushita M., La Perle K., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007, 13:5426-5435.
8. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:725-733.
9. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. NEngl J Med 2013, 368:1509-1518.
10. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
11. Louis C.U., Savoldo B., Dotti G., Pule M., Yvon E., Myers G.D., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
12. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., et al. Aphase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006, 12:6106-6115.
13. Robbins P.F., Dudley M.E., Wunderlich J., El-Gamil M., Li Y.F., Zhou J., et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. JImmunol 2004, 173:7125-7130.
14. Huang J., Khong H.T., Dudley M.E., El-Gamil M., Li Y.F., Rosenberg S.A., et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. JImmunother 2005, 28:258-267.
15. Lamers C.H., Willemsen R., van Elzakker P., van Steenbergen-Langeveld S., Broertjes M., Oosterwijk-Wakka J., et al. Immune responses to transgene and retroviral vector in patients treated with exvivo-engineered T cells. Blood 2011, 117:72-82.
16. Jensen M.C., Popplewell L., Cooper L.J., DiGiusto D., Kalos M., Ostberg J.R., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010, 16:1245-1256.
17. Savoldo B., Ramos C.A., Liu E., Mims M.P., Keating M.J., Carrum G., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. JClin Invest 2011, 121:1822-1826.
18. Maher J., Brentjens R.J., Gunset G., Riviere I., Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002, 20:70-75.
19. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
20. Pule M.A., Straathof K.C., Dotti G., Heslop H.E., Rooney C.M., Brenner M.K. Achimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005, 12:933-941.
21. Ritchie D.S., Neeson P.J., Khot A., Peinert S., Tai T., Tainton K., et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013, 21:2122-2129.
22. Till B.G., Jensen M.C., Wang J., Qian X., Gopal A.K., Maloney D.G., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119:3940-3950.
23. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
24. Zhou J., Shen X., Huang J., Hodes R.J., Rosenberg S.A., Robbins P.F. Telomere length of transferred lymphocytes correlates with invivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. JImmunol 2005, 175:7046-7052.
25. Schwartzentruber D.J., Hom S.S., Dadmarz R., White D.E., Yannelli J.R., Steinberg S.M., et al. Invitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. JClin Oncol 1994, 12:1475-1483.
26. Itzhaki O., Hovav E., Ziporen Y., Levy D., Kubi A., Zikich D., et al. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. JImmunother 2011, 34:212-220.
27. Dudley M.E., Gross C.A., Somerville R.P., Hong Y., Schaub N.P., Rosati S.F., et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. JClin Oncol 2013, 31:2152-2159.
28. Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., et al. Ahuman memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297.
29. Lugli E., Dominguez M.H., Gattinoni L., Chattopadhyay P.K., Bolton D.L., Song K., et al. Superior T memory stem cell persistence supports long-lived T cell memory. JClin Invest 2013, 123:594-599.
30. June C.H., Ledbetter J.A., Linsley P.S., Thompson C.B. Role of the CD28 receptor in T-cell activation. Immunol Today 1990, 11:211-216.
31. Porter D.L., Levine B.L., Bunin N., Stadtmauer E.A., Luger S.M., Goldstein S., et al. Aphase 1 trial of donor lymphocyte infusions expanded and activated exvivo via CD3/CD28 costimulation. Blood 2006, 107:1325-1331.
32. Yu S.S., Nukaya I., Enoki T., Chatani E., Kato A., Goto Y., et al. Invivo persistence of genetically modified T cells generated exvivo using the fibronectin CH296 stimulation method. Cancer Gene Ther 2008, 15:508-516.
33. Caserta S., Alessi P., Basso V., Mondino A. IL-7 is superior to IL-2 for exvivo expansion of tumour-specific CD4(+) T cells. Eur J Immunol 2010, 40:470-479.
34. Cha E., Graham L., Manjili M.H., Bear H.D. IL-7+ IL-15 are superior to IL-2 for the exvivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors invivo. Breast Cancer Res Treat 2010, 122:359-369.
35. Gomez-Eerland R., Nuijen B., Heemskerk B., van Rooij N., van den Berg J.H., Beijnen J.H., et al. Manufacture of gene-modified human T cells with a memory stem/central memory phenotype. Human Gene Ther Methods 2014, 25:277-287.
36. Cieri N., Camisa B., Cocchiarella F., Forcato M., Oliveira G., Provasi E., et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013, 121:573-584.
37. Xu Y., Zhang M., Ramos C.A., Durett A., Liu E., Dakhova O., et al. Closely related T-memory stem cells correlate with invivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014, 123:3750-3759.
38. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. NEngl J Med 2013, 369:134-144.
39. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEngl J Med 2012, 366:2455-2465.
40. Gargett T., Fraser C., Dotti G., Yvon E., Brown M. BRAF and MEK inhibition variably affects GD2-specific chimeric antigen receptor (CAR) T-cell function invitro. JImmunother 2015, 38:12-23.
41. Yvon E., Del Vecchio M., Savoldo B., Hoyos V., Dutour A., Anichini A., et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res 2009, 15:5852-5860.
42. Di Stasi A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. NEngl J Med 2011, 365:1673-1683.
43. Gargett T., Brown M.P. The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol 2014, 5:235.
44. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
45. Lugli E., Gattinoni L., Roberto A., Mavilio D., Price D.A., Restifo N.P., et al. Identification, isolation and invitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc 2013, 8:33-42.
46. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
47. Leitner J., Rieger A., Pickl W.F., Zlabinger G., Grabmeier-Pfistershammer K., Steinberger P. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog 2013, 9:e1003253.
48. Salek-Ardakani S., Schoenberger S.P. Tcell exhaustion: a means or an end?. Nat Immunol 2013, 14:531-533.